AR041210A1 - Compuesto de piridazinona o piridona y uso farmaceutico del mismo - Google Patents

Compuesto de piridazinona o piridona y uso farmaceutico del mismo

Info

Publication number
AR041210A1
AR041210A1 ARP030103257A ARP030103257A AR041210A1 AR 041210 A1 AR041210 A1 AR 041210A1 AR P030103257 A ARP030103257 A AR P030103257A AR P030103257 A ARP030103257 A AR P030103257A AR 041210 A1 AR041210 A1 AR 041210A1
Authority
AR
Argentina
Prior art keywords
halogen
lower alkyl
hydroxy
disease
acyl
Prior art date
Application number
ARP030103257A
Other languages
English (en)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002951245A external-priority patent/AU2002951245A0/en
Priority claimed from AU2002952245A external-priority patent/AU2002952245A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR041210A1 publication Critical patent/AR041210A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a compuestos de piridazinona o piridona de fórmula (1) y una sal del mismo que son antagonistas de la adenosina y son útiles para la prevención y/o el tratamiento de depresión, demencia (por ejemplo, mal de Alzheimer, demenciacerebrovascular, demencia que acompana al mal de Parkinson, etc), mal de Parkinson, ansiedad, dolor, enfermedad cerebrovascular (por ejemplo ataque apopléjico, etc), insuficiencia cardíaca y similares. También reivindica proceso de obtención,composición farmacéutica y uso. Reivindicación 1: Un compuesto de piridazinona o piridona de la siguiente fórmula (1) caracterizado porque X es como se muestra en los restos de fórmula (2) o (3), Y es N o CH; R1 es H o alquilo inferioropcionalmente sustituido; R2 es H o halógeno; R3 es H, alquilo inferior, alcoxi inferior, halógeno, hidroxi, ciano, amino, carbamoilo, tiocarbamoilo, arilo, acilo, acilamino o grupo heterocíclico, cada uno de los cuales puede estar opcionalmentesustituido; R4 es H, alquilo inferior, alcoxi inferior, halógeno, hidroxi, ciano, amino, carbamoilo, acilo, acilamino o -A-R7 donde A es -CH=CH- o -CH=N-, y R7 es alquilo inferior, alcoxi inferior, hidroxi, ciano, acilo, arilalcoxi (inferior) oaciloxi, cada uno de los cuales puede estar opcionalmente sustituido; R5 es H, alquilo inferior, alcoxi inferior, halógeno, hidroxi, cada uno de los cuales puede estar opcionalmente sustituido; y R6 es H o halógeno; o una sal del mismo.
ARP030103257A 2002-09-06 2003-09-08 Compuesto de piridazinona o piridona y uso farmaceutico del mismo AR041210A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002951245A AU2002951245A0 (en) 2002-09-06 2002-09-06 Pyridazinone compound and pharmaceutical use thereof
AU2002952245A AU2002952245A0 (en) 2002-10-24 2002-10-24 Pyridazinone compound and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
AR041210A1 true AR041210A1 (es) 2005-05-11

Family

ID=31979113

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103257A AR041210A1 (es) 2002-09-06 2003-09-08 Compuesto de piridazinona o piridona y uso farmaceutico del mismo

Country Status (4)

Country Link
US (1) US20040067955A1 (es)
AR (1) AR041210A1 (es)
TW (1) TW200406400A (es)
WO (1) WO2004022540A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938296A (zh) * 2004-04-01 2007-03-28 安斯泰来制药有限公司 作为腺苷拮抗剂的吡嗪衍生物及其制药用途
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
MY148634A (en) 2006-07-25 2013-05-15 Cephalon Inc Pyridazinone derivatives
MX2014015156A (es) * 2012-06-12 2015-08-06 Abbvie Inc Derivados de piridinona y piridazinona.
AP2015008783A0 (en) * 2013-03-29 2015-10-31 Takeda Pharmaceutical 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors
MX2018004892A (es) 2015-10-23 2018-12-10 Array Biopharma Inc Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr.
MX2019012174A (es) * 2017-04-11 2019-11-25 Mitsui Chemicals Agro Inc Compuestos de piridona y fungicidas agricolas y horticolas que contienen los mismos como ingredientes activos.
CN113226322A (zh) * 2018-10-30 2021-08-06 诺维逊生物股份有限公司 作为bet抑制剂的杂环化合物
EP3997070A4 (en) 2019-07-02 2023-07-26 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
US4431651A (en) * 1982-11-18 1984-02-14 Sterling Drug Inc. 2-Pyridinones and their use as cardiotonic agents
IL89123A (en) * 1989-01-31 1993-08-18 Ilana Tamir Method for determination of ldl-cholesterol
US5085784A (en) * 1989-04-07 1992-02-04 Cuno, Incorporated Use of cationic charge modified filter media
US5290703A (en) * 1992-12-14 1994-03-01 Miles, Inc. Method for the separation of high density lipoprotein from blood samples
JPH11508267A (ja) * 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
US6118002A (en) * 1999-03-02 2000-09-12 Wyckoff Chemical Company, Inc. Purification of 1,2-dihydro-6-alkyl-2-oxo-5-(pyridinyl)-nicotinonitriles
US6437102B1 (en) * 1999-11-24 2002-08-20 Bayer Corporation Method of separating prions from biological materials
MXPA03001136A (es) * 2000-08-11 2003-06-24 Eisai Co Ltd Compuesto de 2-aminopiridina y uso medico del mismo.

Also Published As

Publication number Publication date
US20040067955A1 (en) 2004-04-08
WO2004022540A2 (en) 2004-03-18
TW200406400A (en) 2004-05-01
WO2004022540A3 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR053301A1 (es) Derivados de pirazina y su uso farmaceutico
AR041210A1 (es) Compuesto de piridazinona o piridona y uso farmaceutico del mismo
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
PE20080266A1 (es) 4-amino-pirido[3,2-e]pirazinas, su uso como inhibidores de fosfodiesterasa 10 y procesos para su preparacion
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
PE20070832A1 (es) Derivados de piridazinona como inhibidores de la tirosina quinasa
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
TW200736257A (en) Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
AR051095A1 (es) Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
PE20020228A1 (es) Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PA8783501A1 (es) Derivados de quinaxolina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
PE20081377A1 (es) Compuestos de tiazol pirazolopirimidina
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
AR057817A1 (es) Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal